{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:53:07Z","timestamp":1790751187144,"version":"4.1.0"},"reference-count":680,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1124\/pr.115.011411","type":"journal-article","created":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T04:03:14Z","timestamp":1451620994000},"page":"168-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":234,"title":["Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions"],"prefix":"10.1016","volume":"68","author":[{"given":"Janne T.","family":"Backman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Filppula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pertti J.","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pr.115.011411_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature11632","article-title":"An integrated map of genetic variation from 1,092 human genomes","volume":"491","author":"Abecasis","year":"2012","journal-title":"Nature"},{"key":"10.1124\/pr.115.011411_bib2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03601230902997766","article-title":"An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes","volume":"44","author":"Abass","year":"2009","journal-title":"J Environ Sci Health B"},{"key":"10.1124\/pr.115.011411_bib3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1124\/dmd.114.058834","article-title":"Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis","volume":"42","author":"Achour","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib4","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1128\/AAC.00673-07","article-title":"Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria","volume":"52","author":"Adjei","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.115.011411_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat Methods"},{"key":"10.1124\/pr.115.011411_bib6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/17425250902970998","article-title":"Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?","volume":"5","author":"Ag\u00fandez","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"10.1124\/pr.115.011411_bib7","first-page":"272","article-title":"Effects of co-trimoxazole co-administration on the pharmacokinetics of amodiaquine in healthy volunteers","volume":"7","author":"Akande","year":"2015","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1124\/pr.115.011411_bib8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/00498254.2014.989935","article-title":"Inhibitory effect of six herbal extracts on CYP2C8 enzyme activity in human liver microsomes","volume":"45","author":"Albassam","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib9","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1124\/dmd.108.020347","article-title":"In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase","volume":"36","author":"Albrecht","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/bdd.1793","article-title":"Identification of human cytochrome P450 enzymes involved in the metabolism of a novel \u043a-opioid receptor agonist, nalfurafine hydrochloride","volume":"33","author":"Ando","year":"2012","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.115.011411_bib11","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/bjc.1998.649","article-title":"Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent","volume":"78","author":"Ando","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1124\/pr.115.011411_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1479-7364-3-1-7","article-title":"Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers","volume":"3","author":"Aquilante","year":"2008","journal-title":"Hum Genomics"},{"key":"10.1124\/pr.115.011411_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2125.2012.04343.x","article-title":"Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone","volume":"75","author":"Aquilante","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/FPC.0b013e3283653b27","article-title":"PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8","volume":"23","author":"Aquilante","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/pr.115.011411_bib15","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/phar.1292","article-title":"Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers","volume":"33","author":"Aquilante","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1124\/pr.115.011411_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejps.2007.09.003","article-title":"Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine","volume":"32","author":"Arbus","year":"2007","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/pr.115.011411_bib17","first-page":"13","article-title":"Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the mozambican population","volume":"20","author":"Arnaldo","year":"2013","journal-title":"Malays J Med Sci"},{"key":"10.1124\/pr.115.011411_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00228-011-1177-2","article-title":"Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers","volume":"68","author":"Arun","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharep.2014.08.010","article-title":"Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population","volume":"67","author":"Arun Kumar","year":"2015","journal-title":"Pharmacol Rep"},{"key":"10.1124\/pr.115.011411_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/dmd.31.4.476","article-title":"Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans","volume":"31","author":"Attar","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib21","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1124\/dmd.109.029728","article-title":"CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe","volume":"37","author":"Backman","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib22","unstructured":"Backman JT, Kajosaari LI, Neuvonen M, Neuvonen PJ (2003) Trimethoprim increases the plasma concentrations of cerivastatin by inhibiting its CYP2C8-mediated metabolism, Abstract in 8th European ISSX Meeting, Dijon, France (April 27-May 1, 2003)."},{"key":"10.1124\/pr.115.011411_bib23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2000.108507","article-title":"Plasma concentrations of active simvastatin acid are increased by gemfibrozil","volume":"68","author":"Backman","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1067\/mcp.2002.128469","article-title":"Gemfibrozil greatly increases plasma concentrations of cerivastatin","volume":"72","author":"Backman","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib25","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1128\/AAC.00018-14","article-title":"Metabolic drug-drug interaction potential of macrolactin A and 7-O-succinyl macrolactin A assessed by evaluating cytochrome P450 inhibition and induction and UDP-glucuronosyltransferase inhibition in vitro","volume":"58","author":"Bae","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.115.011411_bib26","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/tx900105n","article-title":"Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition","volume":"22","author":"Baer","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/pr.115.011411_bib27","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0006-2952(02)01354-0","article-title":"CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes","volume":"64","author":"Bahadur","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib28","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1601-0825.2012.01912.x","article-title":"New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw","volume":"18","author":"Balla","year":"2012","journal-title":"Oral Dis"},{"key":"10.1124\/pr.115.011411_bib29","doi-asserted-by":"crossref","first-page":"29614","DOI":"10.1074\/jbc.M114.583062","article-title":"Targeting of splice variants of human cytochrome P450 2C8 (CYP2C8) to mitochondria and their role in arachidonic acid metabolism and respiratory dysfunction","volume":"289","author":"Bajpai","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.011411_bib30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2125.1999.00030.x","article-title":"Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone","volume":"48","author":"Baldwin","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib31","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1124\/dmd.107.015438","article-title":"Hepatic metabolism of MK-0457, a potent aurora kinase inhibitor: interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase","volume":"35","author":"Ballard","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib32","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.bbrc.2005.02.103","article-title":"Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily","volume":"329","author":"Barbosa-Sicard","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.115.011411_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1211\/0022357991772628","article-title":"Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5","volume":"51","author":"Baune","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/pr.115.011411_bib34","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0090-9556(24)15027-1","article-title":"Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism","volume":"27","author":"Becquemont","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/tpj.2010.19","article-title":"Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer","volume":"11","author":"Bergmann","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/pr.115.011411_bib36a","article-title":"Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma","author":"Bergmann","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.0306-5251.2003.01862.x","article-title":"CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide","volume":"56","author":"Bidstrup","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2125.2005.02516.x","article-title":"The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide","volume":"61","author":"Bidstrup","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00228-004-0746-z","article-title":"Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide","volume":"60","author":"Bidstrup","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0090-9556(24)15052-0","article-title":"Human cytochrome P450 maximal activities in pediatric versus adult liver","volume":"28","author":"Blanco","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib40","first-page":"321","article-title":"Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved","volume":"25","author":"Boberg","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00228-010-0840-3","article-title":"Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients","volume":"66","author":"Bogman","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1021\/tx980136z","article-title":"Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds","volume":"12","author":"Bonierbale","year":"1999","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/pr.115.011411_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.abb.2004.03.032","article-title":"Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes","volume":"426","author":"Bort","year":"2004","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/pr.115.011411_bib44","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1124\/dmd.106.011189","article-title":"Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes","volume":"34","author":"Bu","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib45","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1179\/joc.2003.15.3.266","article-title":"Drug interactions of paclitaxel metabolism in human liver microsomes","volume":"15","author":"Bun","year":"2003","journal-title":"J Chemother"},{"key":"10.1124\/pr.115.011411_bib46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/IJWH.S19309","article-title":"Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women","volume":"3","author":"Burnett","year":"2011","journal-title":"Int J Womens Health"},{"key":"10.1124\/pr.115.011411_bib47","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF00168924","article-title":"Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans","volume":"353","author":"Busse","year":"1995","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pr.115.011411_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/18723128112069990010","article-title":"Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine","volume":"7","author":"Bymaster","year":"2013","journal-title":"Drug Metab Lett"},{"key":"10.1124\/pr.115.011411_bib49","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/dmd.32.6.584","article-title":"Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes","volume":"32","author":"Cai","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib50","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1124\/dmd.107.015875","article-title":"In vitro prediction and in vivo verification of enantioselective human tofisopam metabolite profiles","volume":"35","author":"Cameron","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib36b","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1167\/iovs.14-14216","article-title":"The role of cytochrome P450 epoxygenases in retinal angiogenesis","volume":"55","author":"Capozzi","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/pr.115.011411_bib459","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.115.065763","article-title":"In vitro metabolism of montelukast by cytochrome P450s (CYPs) and UDP-glucuronosyltransferases (UGTs)","author":"Cardoso","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib51","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/infdis\/jis736","article-title":"CYP2C8 status of patients with malaria influences selection of Plasmodium falciparum pfmdr1 alleles after amodiaquine-artesunate treatment","volume":"207","author":"Cavaco","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.115.011411_bib52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1515\/CCLM.2006.030","article-title":"CYP2C8 polymorphism among the Portuguese","volume":"44","author":"Cavaco","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"10.1124\/pr.115.011411_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00228-004-0871-8","article-title":"CYP2C8 polymorphism frequencies among malaria patients in Zanzibar","volume":"61","author":"Cavaco","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib54","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.0306-5251.2003.01919.x","article-title":"Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human","volume":"56","author":"Cazali","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib55","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pds.977","article-title":"Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy","volume":"13","author":"Chang","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1124\/pr.115.011411_bib56","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1124\/dmd.109.026997","article-title":"Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro","volume":"37","author":"Chang","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib57","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1124\/dmd.108.022970","article-title":"Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro","volume":"36","author":"Chang","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib58","first-page":"5629","article-title":"Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes","volume":"53","author":"Chang","year":"1993","journal-title":"Cancer Res"},{"key":"10.1124\/pr.115.011411_bib59","first-page":"1946","article-title":"Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines","volume":"57","author":"Chang","year":"1997","journal-title":"Cancer Res"},{"key":"10.1124\/pr.115.011411_bib60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","article-title":"Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation","volume":"108","author":"Chang","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib61","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/dmd.105.006148","article-title":"Novel metabolites of buprenorphine detected in human liver microsomes and human urine","volume":"34","author":"Chang","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/bs.apha.2015.04.005","article-title":"Cytochrome P450-CYP2 family-epoxygenase role in inflammation and cancer","volume":"74","author":"Chen","year":"2015","journal-title":"Adv Pharmacol"},{"key":"10.1124\/pr.115.011411_bib63","doi-asserted-by":"crossref","first-page":"889","DOI":"10.5414\/CP202121","article-title":"Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects","volume":"52","author":"Chen","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib64","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1124\/jpet.108.148916","article-title":"Identification of human CYP2C8 as a retinoid-related orphan nuclear receptor target gene","volume":"329","author":"Chen","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib65","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2174\/138920009789375397","article-title":"The transcriptional regulation of the human CYP2C genes","volume":"10","author":"Chen","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1124\/pr.115.011411_bib66","first-page":"1216","article-title":"Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes","volume":"29","author":"Cherstniakova","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib67","first-page":"1022","article-title":"Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans","volume":"25","author":"Chiba","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib68","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/dmd.112.046276","article-title":"Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone","volume":"41","author":"Choi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib69","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0024-3205(85)90285-1","article-title":"Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans","volume":"36","author":"Churchill","year":"1985","journal-title":"Life Sci"},{"key":"10.1124\/pr.115.011411_bib70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4161\/org.27911","article-title":"Time-dependent expression of cytochrome p450 epoxygenases during human prenatal development","volume":"10","author":"Cizkova","year":"2014","journal-title":"Organogenesis"},{"key":"10.1124\/pr.115.011411_bib71","first-page":"386","article-title":"Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation","volume":"54","author":"Cresteil","year":"1994","journal-title":"Cancer Res"},{"key":"10.1124\/pr.115.011411_bib72","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/dmd.30.4.438","article-title":"Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship","volume":"30","author":"Cresteil","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib73","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","article-title":"Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid","volume":"11","author":"Dai","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/pr.115.011411_bib74","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0022-3565(25)24028-9","article-title":"Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9","volume":"271","author":"Daikh","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib75","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2217\/pgs.09.82","article-title":"Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies","volume":"10","author":"Daily","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1124\/pr.115.011411_bib76","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/AAC.01279-08","article-title":"In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin","volume":"53","author":"Damle","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.115.011411_bib77","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1124\/dmd.112.046169","article-title":"In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates","volume":"40","author":"Davis","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-200241020-00003","article-title":"Pharmaokinetic profile of zafirlukast","volume":"41","author":"Dekhuijzen","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib79","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1124\/dmd.104.002097","article-title":"Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17beta-glucuronide oxidation to 2-hydroxy-estradiol-17beta-glucuronide by CYP 2C8","volume":"33","author":"Delaforge","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib80","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1124\/dmd.106.012823","article-title":"Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues","volume":"35","author":"Delozier","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib81","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00228-005-0042-6","article-title":"Effect of gemfibrozil on the pharmacokinetics of pioglitazone","volume":"61","author":"Deng","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib82","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1185\/03007990902790928","article-title":"In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates","volume":"25","author":"Derks","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/pr.115.011411_bib83","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF03192303","article-title":"Human liver microsomal metabolism of paclitaxel and drug interactions","volume":"23","author":"Desai","year":"1998","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib84","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0090-9556(24)15349-4","article-title":"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies","volume":"28","author":"Desta","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib85","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0022-3565(24)29409-X","article-title":"Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A","volume":"298","author":"Desta","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib86","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/jpet.104.065607","article-title":"Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6","volume":"310","author":"Desta","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib87","first-page":"23","article-title":"A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry","volume":"29","author":"Dierks","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib88","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.toxlet.2014.08.004","article-title":"Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse","volume":"230","author":"Dinger","year":"2014","journal-title":"Toxicol Lett"},{"key":"10.1124\/pr.115.011411_bib89","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1124\/dmd.107.016089","article-title":"Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions","volume":"35","author":"Dixit","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib90","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/0006-291X(90)90889-U","article-title":"Phenytoin 4-hydroxylation by rabbit liver P450IIC3 and identification of orthologs in human liver microsomes","volume":"166","author":"Doecke","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.115.011411_bib91","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.tiv.2010.09.001","article-title":"Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities","volume":"25","author":"Doehmer","year":"2011","journal-title":"Toxicol In Vitro"},{"key":"10.1124\/pr.115.011411_bib92","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1124\/dmd.32.7.699","article-title":"Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes","volume":"32","author":"Donato","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib93","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/aps.2010.218","article-title":"Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib","volume":"32","author":"Dong","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/pr.115.011411_bib94","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cell.2008.09.002","article-title":"Retinoic acid synthesis and signaling during early organogenesis","volume":"134","author":"Duester","year":"2008","journal-title":"Cell"},{"key":"10.1124\/pr.115.011411_bib95","doi-asserted-by":"crossref","first-page":"33309","DOI":"10.1074\/jbc.C100375200","article-title":"Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR","volume":"276","author":"Dussault","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.011411_bib36c","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1124\/dmd.109.027011","article-title":"Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function","volume":"37","author":"Dutheil","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib96","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0006-2952(94)90097-3","article-title":"The metabolism of zidovudine by human liver microsomes in vitro: formation of 3\u2032-amino-3\u2032-deoxythymidine","volume":"48","author":"Eagling","year":"1994","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 2","key":"10.1124\/pr.115.011411_bib97","doi-asserted-by":"crossref","first-page":"S234","DOI":"10.1055\/s-2000-8525","article-title":"Clinical pharmacokinetics of pioglitazone","volume":"108","author":"Eckland","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1124\/pr.115.011411_bib98","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2125.2007.02943.x","article-title":"Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination","volume":"64","author":"Elliot","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib99","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/002215540405200403","article-title":"Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues","volume":"52","author":"Enayetallah","year":"2004","journal-title":"J Histochem Cytochem"},{"key":"10.1124\/pr.115.011411_bib101","unstructured":"EMA (2012a) Assessment report: Zytiga. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/002321\/WC500137814.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib102","unstructured":"EMA (2012b) Guideline on the investigation of drug interactions. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib103","unstructured":"EMA (2012c) Summary of product characteristics: Xalkori. Available from: http:\/\/ec.europa.eu\/health\/documents\/community-register\/2012\/20121023124213\/anx_124213_en.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib104","unstructured":"EMA (2012d) Zelboraf, Procedural steps taken and scientific information after the authorisation. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/002409\/WC500137805.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib105","unstructured":"EMA (2014) Summary of product characteristics: Simbrinza. Available from: http:\/\/ec.europa.eu\/health\/documents\/community-register\/2014\/20140718129060\/anx_129060_en.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib106","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0009-9236(96)90001-6","article-title":"Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation","volume":"59","author":"Engel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib107","first-page":"579","article-title":"A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer","volume":"6","author":"English","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1124\/pr.115.011411_bib108","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1021\/tx4001144","article-title":"Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry","volume":"26","author":"Erve","year":"2013","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/pr.115.011411_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/bdd.1947","article-title":"In vitro inhibition and induction of human cytochrome P450 enzymes by SIPI5357, a potential antidepressant","author":"Fan","year":"2015","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.115.011411_bib110","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/11587310-000000000-00000","article-title":"The pregnane X receptor agonist St John\u2019s Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide","volume":"50","author":"Fan","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib111","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3109\/13880209.2013.796393","article-title":"The potential of Hypoxis hemerocallidea for herb-drug interaction","volume":"51","author":"Fasinu","year":"2013","journal-title":"Pharm Biol"},{"key":"10.1124\/pr.115.011411_bib112","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/dmd.112.049593","article-title":"The potential of Sutherlandia frutescens for herb-drug interaction","volume":"41","author":"Fasinu","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib113","unstructured":"FDA (1998) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Singulair. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/020829s000_Singular_Clin_Pharm_Biopharm.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib114","unstructured":"FDA (1999) Actos prescribing information. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1999\/21073lbl.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib115","unstructured":"FDA (2001) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Gleevec. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21-335_Gleevec_biopharmr_P1.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib116","unstructured":"FDA (2004) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Tarceva. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/21-743_Tarceva_biopharmr.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib117","unstructured":"FDA (2005a) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Exjade. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021882_s000_Exjade_BioPharmr.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib118","unstructured":"FDA (2005b) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review: Nevaxar. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021923_s000_Nexavar_BioPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib119","unstructured":"FDA (2006a) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Sprycel. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021986s000_Sprycel__ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib120","unstructured":"FDA (2006b) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review: Sutent. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021938_S000_Sutent_BioPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib121","unstructured":"FDA (2007a) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Bystolic. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/021742s000_ClinPharmR_P1.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib122","unstructured":"FDA (2007b) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Neupro. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/021829s000_ClinPharmR_P2.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib123","unstructured":"FDA (2007c) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Tasigna. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022068s000_ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib124","unstructured":"FDA (2007d) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Torisel. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022088s000_ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib125","unstructured":"FDA (2007e) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Tykerb. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022059s000_ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib126","unstructured":"FDA (2008a) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Intelence. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/022187s000_ClinPharmR_P5.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib127","unstructured":"FDA (2008b) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Pristiq. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/021992s000_ClinPharmR_P2.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib128","unstructured":"FDA (2008c) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Promacta. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/022291s000_ClinPharmR_P1.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib129","unstructured":"FDA (2009a) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Multaq. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022425s000_ClinPharm_P1.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib130","unstructured":"FDA (2009b) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Tyvaso. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022387s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib131","unstructured":"FDA (2009c) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Uloric. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/021856s000_ClinPharmR_P1.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib132","unstructured":"FDA (2009d) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Votrient. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022465s000_ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib133","unstructured":"FDA (2010a) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Jevtana. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/201023s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib134","unstructured":"FDA (2010b) Centre for drug evaluation and research: Pharmacology review(s): Ella. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022474s000PharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib135","unstructured":"FDA (2011a) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Arcapta Neohaler. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022383Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib136","unstructured":"FDA (2011b) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Brilinta. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022433Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib137","unstructured":"FDA (2011c) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Edarbi. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/200796Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib138","unstructured":"FDA (2011d) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Edurant. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202022Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib139","unstructured":"FDA (2011e) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Xalkori. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202570Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib140","unstructured":"FDA (2011f) Centre for drug evaluation and research: Pharmacology review(s): Edarbi. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/200796Orig1s000PharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib141","unstructured":"FDA (2011g) Centre for drug evaluation and research: Pharmacology review(s): Viibryd. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022567Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib142","unstructured":"FDA (2012a) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Aubagio. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202992Orig1s000ClinpharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib143","unstructured":"FDA (2012b) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Belviq. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/022529Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib144","unstructured":"FDA (2012c) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Cometriq. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203756Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib145","unstructured":"FDA (2012d) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Eliquis. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202155Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib146","unstructured":"FDA (2012e) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Iclusig. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203469Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib147","unstructured":"FDA (2012f) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Inlyta. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202324Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib148","unstructured":"FDA (2012g) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Kalydeco. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203188Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib149","unstructured":"FDA (2012h) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Signifor. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/200677Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib150","unstructured":"FDA (2012i) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Stivarga. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203085Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib151","unstructured":"FDA (2012j) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Stribild. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203100Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib152","unstructured":"FDA (2012k) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Xtandi. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203415Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib153","unstructured":"FDA (2012l) Centre for drug evaluation and research: Pharmacology review(s): Aubagio. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202992Orig1s000PharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib154","unstructured":"FDA (2013a) Actos prescribing information. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021073s046lbl.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib155","unstructured":"FDA (2013b) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Adempas. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204819Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib156","unstructured":"FDA (2013c) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Breo Ellipta. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204275Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib157","unstructured":"FDA (2013d) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Imbruvica. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/205552Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib158","unstructured":"FDA (2013e) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Invokana. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204042Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib159","unstructured":"FDA (2013f) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Mekinist. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204114Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib160","unstructured":"FDA (2013g) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Nesina. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/022271Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib161","unstructured":"FDA (2013h) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Olysio. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/205123Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib162","unstructured":"FDA (2013i) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Osphena. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203505Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib163","unstructured":"FDA (2013j) Centre for drug evaluation and research: Pharmacology review(s): Brintellix. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204447Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib164","unstructured":"FDA (2013k) Centre for drug evaluation and research: Pharmacology review(s): Opsumit. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204410Orig1s000PharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib165","unstructured":"FDA (2014a) Avandia, prescribing information. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021071s047s048s049lbl.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib166","unstructured":"FDA (2014b) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Akynzeo. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205718Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib167","unstructured":"FDA (2014c) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Beleodaq. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206256Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib168","unstructured":"FDA (2014d) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Ofev. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205832Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib169","unstructured":"FDA (2014e) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Otezla. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205437Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib170","unstructured":"FDA (2014f) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Respimat. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/203108Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib171","unstructured":"FDA (2014g) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Viekira Pak. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206619Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib172","unstructured":"FDA (2014h) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Zydelig. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206545Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib173","unstructured":"FDA (2014i) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Zykadia. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205755Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib174","unstructured":"FDA (2014j) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review: Belsomra. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/204569Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib175","unstructured":"FDA (2014k) Centre for drug evaluation and research: Pharmacology review(s): Viekira Pak. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206619Orig1s000PharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib176","unstructured":"FDA (2014l) Centre for drug evaluation and research: Pharmacology review(s): Zontivity. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/204886Orig1s000PharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib177","unstructured":"FDA (2014m) Hetlioz, prescribing information. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205677Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib178","unstructured":"FDA (2015a) Centre for drug evaluation and research: Clinical pharmacology and biopharmaceutics review(s): Lenvima. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206947Orig1s000ClinPharmR.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib179","unstructured":"FDA (2015b) Reyataz prescribing information. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021567s037,206352s002lbl.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib180","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1124\/dmd.110.033886","article-title":"Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes","volume":"38","author":"Feidt","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib181","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cbi.2013.12.008","article-title":"In vitro identification of cytochrome P450 isoforms responsible for the metabolism of 1-hydroxyl-2,3,5-trimethoxy-xanthone purified from Halenia elliptica D. Don","volume":"210","author":"Feng","year":"2014","journal-title":"Chem Biol Interact"},{"key":"10.1124\/pr.115.011411_bib182","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1124\/mol.105.013169","article-title":"Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha","volume":"68","author":"Ferguson","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.115.011411_bib183","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1124\/dmd.110.037689","article-title":"Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations","volume":"39","author":"Filppula","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib184","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.115.011411_bib185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/dmd.112.048017","article-title":"Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response","volume":"41","author":"Filppula","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib186","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1124\/dmd.114.057695","article-title":"In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors","volume":"42","author":"Filppula","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib187","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/clpt.2013.92","article-title":"Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite","volume":"94","author":"Filppula","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib188","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0090-9556(24)14919-7","article-title":"The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions","volume":"27","author":"Fischer","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib189","first-page":"802","article-title":"The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite","volume":"26","author":"Fischer","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib190","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00280-011-1585-0","article-title":"Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I\/II pharmacokinetic interaction study","volume":"68","author":"Flaherty","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pr.115.011411_bib191","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1124\/pr.113.007781","article-title":"The pharmacology of the cytochrome P450 epoxygenase\/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease","volume":"66","author":"Fleming","year":"2014","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.115.011411_bib192","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/clpt.2011.295","article-title":"A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel","volume":"91","author":"Floyd","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib193","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1124\/dmd.109.028043","article-title":"In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract","volume":"37","author":"Foti","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib194","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1124\/dmd.112.047928","article-title":"Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors","volume":"40","author":"Foti","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.chroma.2005.11.116","article-title":"Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction","volume":"1112","author":"Frank","year":"2006","journal-title":"J Chromatogr A"},{"key":"10.1124\/pr.115.011411_bib196","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.011411_bib197","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/00498250400015319","article-title":"Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors","volume":"34","author":"Fujino","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib198","first-page":"701","article-title":"Studies on the interaction between fibrates and statins using human hepatic microsomes","volume":"53","author":"Fujino","year":"2003","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/pr.115.011411_bib199","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0378-4347(01)00141-4","article-title":"Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay--inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase","volume":"757","author":"Fujino","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1124\/pr.115.011411_bib200","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1515\/DMDI.2003.19.3.161","article-title":"Interaction between fibrates and statins--metabolic interactions with gemfibrozil","volume":"19","author":"Fujino","year":"2003","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1124\/pr.115.011411_bib201","unstructured":"Furuta S, Kamada E, Sugimoto T, Kawabata Y, Wu XC, Skibbe J, Usuki E, Parkinson A, and Kurimoto T (2004) Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338, in 2nd Pharmaceutical Sciences World Congress, Kyoto, Japan (May 31-June 5, 2004). Available from: http:\/\/www.cerep.fr\/cerep\/Users\/pages\/News\/Publications\/92.pdf (Accessed June 18, 2015)"},{"key":"10.1124\/pr.115.011411_bib202","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1124\/dmd.109.029835","article-title":"In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition","volume":"38","author":"Gallemann","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib203","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2125.2010.03772.x","article-title":"Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism","volume":"70","author":"Gan","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib204","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00280-011-1672-2","article-title":"In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin","volume":"69","author":"Gan","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pr.115.011411_bib205","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/00498254.2010.487163","article-title":"Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions","volume":"40","author":"Gao","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib206","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256440","article-title":"Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals","volume":"10","author":"Garc\u00eda-Mart\u00edn","year":"2006","journal-title":"Mol Diagn Ther"},{"key":"10.1124\/pr.115.011411_bib207","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clpt.2004.04.006","article-title":"Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms","volume":"76","author":"Garc\u00eda-Mart\u00edn","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib208","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1074\/jbc.M107228200","article-title":"Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor","volume":"277","author":"Gerbal-Chaloin","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.011411_bib209","first-page":"242","article-title":"Induction of CYP2C genes in human hepatocytes in primary culture","volume":"29","author":"Gerbal-Chaloin","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib210","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1086\/511882","article-title":"Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz","volume":"44","author":"German","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1124\/pr.115.011411_bib211","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/dmd.105.007906","article-title":"Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar)","volume":"34","author":"Ghosal","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib212","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/bdd.374","article-title":"Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes","volume":"24","author":"Ghosal","year":"2003","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.115.011411_bib213","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"Pharmacokinetic drug interaction studies with Enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib214","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/14622416.8.2.187","article-title":"CYP2C8 and antimalaria drug efficacy","volume":"8","author":"Gil","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1124\/pr.115.011411_bib215","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1124\/dmd.106.013938","article-title":"In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid","volume":"35","author":"Gorman","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib216","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/004982599238335","article-title":"Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A","volume":"29","author":"Grace","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib217","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/geno.1995.1149","article-title":"A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24","volume":"28","author":"Gray","year":"1995","journal-title":"Genomics"},{"key":"10.1124\/pr.115.011411_bib218","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1002\/jps.22680","article-title":"Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel\/carboplatin-induced myelosuppression in patients with ovarian cancer","volume":"100","author":"Gr\u00e9en","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/pr.115.011411_bib219","first-page":"598","article-title":"Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase","volume":"25","author":"Grimm","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib220","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib221","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/bja\/80.6.788","article-title":"Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol","volume":"80","author":"Guitton","year":"1998","journal-title":"Br J Anaesth"},{"key":"10.1124\/pr.115.011411_bib222","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1124\/dmd.105.008250","article-title":"Identification of human hepatic cytochrome P450 enzymes involved in the metabolism of 8-prenylnaringenin and isoxanthohumol from hops (Humulus lupulus L.)","volume":"34","author":"Guo","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib223","doi-asserted-by":"crossref","first-page":"12112","DOI":"10.1021\/bi010254c","article-title":"Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19","volume":"40","author":"Ha-Duong","year":"2001","journal-title":"Biochemistry"},{"key":"10.1124\/pr.115.011411_bib224","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2133\/dmpk.23.412","article-title":"Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine","volume":"23","author":"Hagihara","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0006-2952(94)90223-2","article-title":"Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver","volume":"48","author":"Hakkola","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"#cr-split#-10.1124\/pr.115.011411_bib226.1","unstructured":"Hall M, Matthews A, Paul DS, Foster JR, Holding JD, Islam K, and Brandt RD (2007) Interactions of Iclaprim with Human Cytochrome P450 Enzymes, in 8th International ISSX Meeting, Sendai, Japan"},{"key":"#cr-split#-10.1124\/pr.115.011411_bib226.2","unstructured":"(October 9-12). Available from: http:\/\/issx.confex.com\/issx\/intl8\/webprogram\/Paper6798.html (Accessed August 26, 2015)"},{"key":"10.1124\/pr.115.011411_bib227","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00228-005-0938-1","article-title":"Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population","volume":"61","author":"Halling","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib228","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.toxlet.2006.09.011","article-title":"Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes","volume":"167","author":"Hamitouche","year":"2006","journal-title":"Toxicol Lett"},{"key":"10.1124\/pr.115.011411_bib229","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0006-2952(97)00143-3","article-title":"Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C","volume":"54","author":"Hamman","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib230","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1124\/pr.55.4.2","article-title":"Induction of drug metabolism: the role of nuclear receptors","volume":"55","author":"Handschin","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.115.011411_bib231","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1742-7843.2010.00543.x","article-title":"Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel","volume":"107","author":"Hanioka","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib232","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1742-7843.2010.00669.x","article-title":"Influence of CYP2C8*13 and CYP2C8*14 alleles on amiodarone N-deethylation","volume":"108","author":"Hanioka","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib233","first-page":"4026","article-title":"Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme","volume":"54","author":"Harris","year":"1994","journal-title":"Cancer Res"},{"key":"10.1124\/pr.115.011411_bib234","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/0091270003253704","article-title":"Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide","volume":"43","author":"Hatorp","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib235","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.fct.2013.03.041","article-title":"Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro","volume":"57","author":"He","year":"2013","journal-title":"Food Chem Toxicol"},{"key":"10.1124\/pr.115.011411_bib236","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1158\/1078-0432.CCR-05-1152","article-title":"Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel","volume":"11","author":"Henningsson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pr.115.011411_bib237","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-012-2054-0","article-title":"CYP2C8*3 predicts benefit\/risk profile in breast cancer patients receiving neoadjuvant paclitaxel","volume":"134","author":"Hertz","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1124\/pr.115.011411_bib238","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10549-014-2910-1","article-title":"Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy","volume":"145","author":"Hertz","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1124\/pr.115.011411_bib239","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1124\/dmd.105.003830","article-title":"Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population","volume":"33","author":"Hichiya","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib240","first-page":"1480","article-title":"CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson\u2019s disease, as revealed from experiments with recombinant enzymes","volume":"29","author":"Hidestrand","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib241","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","article-title":"Drug-drug interaction between pitavastatin and various drugs via OATP1B1","volume":"34","author":"Hirano","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib242","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1124\/dmd.107.016758","article-title":"Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol","volume":"35","author":"Hiratsuka","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib243","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ejps.2010.12.002","article-title":"Metabolism of hyperforin, the active constituent of St. John\u2019s wort, in human liver microsomes","volume":"42","author":"Hokkanen","year":"2011","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/pr.115.011411_bib244","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/clpt.2013.192","article-title":"Grapefruit juice inhibits the metabolic activation of clopidogrel","volume":"95","author":"Holmberg","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"4, Suppl","key":"10.1124\/pr.115.011411_bib245","doi-asserted-by":"crossref","first-page":"75S","DOI":"10.1177\/1091581813487226","article-title":"Evaluations of in vitro metabolism, drug-drug interactions mediated by reversible and time-dependent inhibition of CYPs, and plasma protein binding of MMB4 DMS","volume":"32","author":"Hong","year":"2013","journal-title":"Int J Toxicol"},{"key":"10.1124\/pr.115.011411_bib246","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1124\/dmd.111.040931","article-title":"Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses","volume":"39","author":"Honkalammi","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib247","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/clpt.2010.358","article-title":"Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans","volume":"89","author":"Honkalammi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib248","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/clpt.2011.313","article-title":"Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses","volume":"91","author":"Honkalammi","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib249","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2174\/138920008786485164","article-title":"Methods for predicting in vivo pharmacokinetics using data from in vitro assays","volume":"9","author":"Houston","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/pr.115.011411_bib250","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2125.2005.02263.x","article-title":"The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects","volume":"59","author":"Hruska","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib251","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1124\/dmd.110.034942","article-title":"CYP2C8 exists as a dimer in natural membranes","volume":"38","author":"Hu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib252","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/dmd.31.7.924","article-title":"Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones","volume":"31","author":"Hu","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib253","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0091270007312153","article-title":"New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process","volume":"48","author":"Huang","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib254","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0006-2952(99)00410-4","article-title":"Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide","volume":"59","author":"Huang","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib255","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1060028013510396","article-title":"Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events","volume":"48","author":"Ibarra-Barrueta","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1124\/pr.115.011411_bib256","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1476-5381.2010.01104.x","article-title":"Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases","volume":"162","author":"Illingworth","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.115.011411_bib257","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.4014\/jmb.1209.09013","article-title":"Effect of TSHAC on human cytochrome P450 activity, and transport mediated by P-glycoprotein","volume":"22","author":"Im","year":"2012","journal-title":"J Microbiol Biotechnol"},{"key":"10.1124\/pr.115.011411_bib258","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/00498250600683262","article-title":"Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences","volume":"36","author":"Inoue","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib259","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/tx950116m","article-title":"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes","volume":"9","author":"Iribarne","year":"1996","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/pr.115.011411_bib260","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1124\/dmd.115.065938","article-title":"Clopidogrel has no clinically meaningful effect on the pharmacokinetics of the OATP1B1 and CYP3A4 substrate simvastatin","volume":"43","author":"Itkonen","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib261","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2125.2005.02515.x","article-title":"Effect of rifampicin on the pharmacokinetics of pioglitazone","volume":"61","author":"Jaakkola","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib262","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.clpt.2004.12.266","article-title":"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone","volume":"77","author":"Jaakkola","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib263","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00228-006-0136-9","article-title":"Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone","volume":"62","author":"Jaakkola","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib264","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1742-7843.2006.pto_437.x","article-title":"Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors","volume":"99","author":"Jaakkola","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib265","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0090-9556(24)15083-0","article-title":"In vitro evaluation of the disposition of A novel cysteine protease inhibitor","volume":"28","author":"Jacobsen","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib266","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0090-9556(24)15086-6","article-title":"Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin","volume":"28","author":"Jacobsen","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib267","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0041-1345(00)02116-3","article-title":"Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD","volume":"33","author":"Jacobsen","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1124\/pr.115.011411_bib268","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1124\/dmd.107.016410","article-title":"Silybin is metabolized by cytochrome P450 2C8 in vitro","volume":"35","author":"Jancov\u00e1","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib269","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1124\/dmd.111.041947","article-title":"Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-\u03b2-glucuronide of gemfibrozil","volume":"39","author":"Jenkins","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib270","doi-asserted-by":"crossref","first-page":"10681","DOI":"10.3390\/molecules180910681","article-title":"Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes","volume":"18","author":"Jeong","year":"2013","journal-title":"Molecules"},{"key":"10.1124\/pr.115.011411_bib271","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1080\/15287394.2014.955906","article-title":"Inhibitory effects of cedrol, \u03b2-cedrene, and thujopsene on cytochrome P450 enzyme activities in human liver microsomes","volume":"77","author":"Jeong","year":"2014","journal-title":"J Toxicol Environ Health A"},{"key":"10.1124\/pr.115.011411_bib272","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.3390\/molecules15096466","article-title":"Effects of eupatilin and jaceosidin on cytochrome p450 enzyme activities in human liver microsomes","volume":"15","author":"Ji","year":"2010","journal-title":"Molecules"},{"key":"10.1124\/pr.115.011411_bib273","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.toxlet.2004.09.001","article-title":"Characterization of human liver cytochrome P450 enzymes involved in the metabolism of a new H+\/K+-ATPase inhibitor KR-60436","volume":"155","author":"Ji","year":"2005","journal-title":"Toxicol Lett"},{"key":"10.1124\/pr.115.011411_bib274","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12272-013-0014-9","article-title":"Evaluation of DA-9801, a new herbal drug for diabetic neuropathy, on metabolism-mediated interaction","volume":"36","author":"Ji","year":"2013","journal-title":"Arch Pharm Res"},{"key":"10.1124\/pr.115.011411_bib275","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fgene.2014.00058","article-title":"CYP2C8 and CYP2C9 mRNA expression profile in the human fetus","volume":"5","author":"Johansson","year":"2014","journal-title":"Front Genet"},{"key":"10.1124\/pr.115.011411_bib276","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cpdd.83","article-title":"Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863","volume":"3","author":"Johnson","year":"2014","journal-title":"Clin Pharmacol Drug Develop"},{"key":"10.1124\/pr.115.011411_bib277","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bbrc.2005.08.190","article-title":"Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases","volume":"338","author":"Johnson","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.115.011411_bib278","first-page":"533","article-title":"In vitro inhibitory activities of the extract of Hibiscus sabdariffa L. (family Malvaceae) on selected cytochrome P450 isoforms","volume":"10","author":"Johnson","year":"2013","journal-title":"Afr J Tradit Complement Altern Medicines"},{"key":"10.1124\/pr.115.011411_bib279","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/bdd.1837","article-title":"In vitro metabolism of obovatol and its effect on cytochrome P450 enzyme activities in human liver microsomes","volume":"34","author":"Joo","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.115.011411_bib280","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00228-005-0093-8","article-title":"Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide","volume":"62","author":"Kajosaari","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib281","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1742-7843.2005.pto_157.x","article-title":"Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin","volume":"97","author":"Kajosaari","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib282","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clpt.2005.11.002","article-title":"Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide","volume":"79","author":"Kajosaari","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib283","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clpt.2005.07.005","article-title":"Cyclosporine markedly raises the plasma concentrations of repaglinide","volume":"78","author":"Kajosaari","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib284","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/00498254.2013.791004","volume":"43","author":"Kalgutkar","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib36d","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/clpt.2008.74","article-title":"Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism","volume":"84","author":"Kalliokoski","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib36e","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2125.2007.02986.x","article-title":"No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone","volume":"65","author":"Kalliokoski","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib285","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2125.1996.tb00169.x","article-title":"Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole","volume":"41","author":"Kamali","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib286","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3109\/00498254.2012.723150","article-title":"In vitro metabolism of the 5-hydroxytryptamine1B receptor antagonist elzasonan","volume":"43","author":"Kamel","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib287","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2125.2010.03791.x","article-title":"In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole","volume":"70","author":"Kamdem","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib288","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ptr.4724","article-title":"Evaluation of food-drug interaction of guava leaf tea","volume":"27","author":"Kaneko","year":"2013","journal-title":"Phytother Res"},{"key":"10.1124\/pr.115.011411_bib289","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1124\/dmd.108.020370","article-title":"Bioactivation of flutamide metabolites by human liver microsomes","volume":"36","author":"Kang","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib290","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s002280050566","article-title":"Effect of itraconazole on cerivastatin pharmacokinetics","volume":"54","author":"Kantola","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib291","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0090-9556(25)08409-0","article-title":"Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes","volume":"24","author":"Karam","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib292","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/00498250902862705","article-title":"Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes","volume":"39","author":"Kara\u017aniewicz-\u0141ada","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib293","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1124\/dmd.113.051664","article-title":"Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development","volume":"41","author":"Karlsson","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib294","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/clpt.2010.73","article-title":"Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast","volume":"88","author":"Karonen","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib295","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00228-010-0908-0","article-title":"The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast","volume":"67","author":"Karonen","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib296","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2125.2011.04086.x","article-title":"CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast","volume":"73","author":"Karonen","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib297","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bcp.2011.06.027","article-title":"Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5","volume":"82","author":"Kaspera","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib298","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FPC.0b013e32833ecace","article-title":"Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis","volume":"20","author":"Kaspera","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/pr.115.011411_bib299","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1124\/dmd.113.056580","article-title":"Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans","volume":"42","author":"Kassahun","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib300","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1124\/dmd.114.062620","article-title":"A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement","volume":"43","author":"Kazmi","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib301","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/00498254.2013.878814","article-title":"In vitro inhibition of human liver cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes by rose bengal: system-dependent effects on inhibitory potential","volume":"44","author":"Kazmi","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib302","unstructured":"Kazmi F, Smith B, Hvenegaard MG, Bendahl L, Gipson A, Buckley D, Ogilvie B, and Parkinson A (2010) Identification of a novel carbamoyl glucuronide as a metabolism-dependent inhibitor of CYP2C8, in 9th International ISSX Meeting, Istanbul, Turkey (September 4-8, 2010). Available from: https:\/\/issx.confex.com\/issx\/intl9\/webprogram\/Paper21723.html (Accessed June 6, 2015)"},{"key":"10.1124\/pr.115.011411_bib303","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib304","first-page":"1","article-title":"Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib","volume":"10","author":"Khan","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib305","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3109\/00498254.2010.549968","article-title":"In vitro metabolism of magnolin and characterization of cytochrome P450 enzymes responsible for its metabolism in human liver microsomes","volume":"41","author":"Kim","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib306","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/rcm.2381","article-title":"In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes","volume":"20","author":"Kim","year":"2006","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/pr.115.011411_bib307","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00280-013-2230-x","article-title":"Effects of \u03b2-lapachone, a new anticancer candidate, on cytochrome P450-mediated drug metabolism","volume":"72","author":"Kim","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pr.115.011411_bib308","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3109\/00498254.2011.590546","article-title":"Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms","volume":"41","author":"Kim","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib309","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00228-004-0815-3","article-title":"Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes","volume":"60","author":"Kim","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib310","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF02976712","article-title":"Cytochrome P450 2C8 and CYP3A4\/5 are involved in chloroquine metabolism in human liver microsomes","volume":"26","author":"Kim","year":"2003","journal-title":"Arch Pharm Res"},{"key":"10.1124\/pr.115.011411_bib311","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/0091270005278407","article-title":"Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects","volume":"45","author":"Kim","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib312","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2125.2006.02764.x","article-title":"Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans","volume":"63","author":"Kim","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib313","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.1158\/1078-0432.CCR-11-1747","article-title":"Phase I\/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma","volume":"17","author":"Kim","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pr.115.011411_bib314","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/rcm.2110","article-title":"High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography\/tandem mass spectrometry","volume":"19","author":"Kim","year":"2005","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/pr.115.011411_bib315","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2133\/dmpk.DMPK-13-RG-019","article-title":"The tyrosine kinase inhibitor nilotinib selectively inhibits CYP2C8 activities in human liver microsomes","volume":"28","author":"Kim","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib316","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1872312811206030002","article-title":"Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins","volume":"6","author":"Kim","year":"2012","journal-title":"Drug Metab Lett"},{"key":"10.1124\/pr.115.011411_bib317","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/00498250701871121","article-title":"Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel activin receptor-like kinase-5 (ALK5) inhibitor","volume":"38","author":"Kim","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib318","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2165\/00003088-200544120-00002","article-title":"Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance","volume":"44","author":"Kirchheiner","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib319","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.clpt.2006.09.008","article-title":"Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype","volume":"80","author":"Kirchheiner","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib320","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/bdd.432","article-title":"Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone","volume":"26","author":"Kitamura","year":"2005","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.115.011411_bib321","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.44","article-title":"Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug","volume":"2","author":"Klieber","year":"2014","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/pr.115.011411_bib322","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-N","article-title":"Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs","volume":"13","author":"Klose","year":"1999","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1124\/pr.115.011411_bib323","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1124\/dmd.105.004010","article-title":"Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide","volume":"33","author":"Kochansky","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib324","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2133\/dmpk.22.276","article-title":"Broad but distinct role of pregnane x receptor on the expression of individual cytochrome p450s in human hepatocytes","volume":"22","author":"Kojima","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib325","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0090-9556(24)15066-0","article-title":"Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments","volume":"28","author":"Komatsu","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib326","first-page":"675","article-title":"Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver","volume":"7","author":"Komatsu","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pr.115.011411_bib327","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0090-9556(24)13674-4","article-title":"Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes","volume":"28","author":"Komatsu","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib328","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1158\/1078-0432.CCR-04-2488","article-title":"Effect of the St. John\u2019s wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures","volume":"11","author":"Komoroski","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pr.115.011411_bib329","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1124\/dmd.115.064790","article-title":"In vitro characterization of the human liver microsomal kinetics and reaction phenotyping of olanzapine metabolism","volume":"43","author":"Korprasertthaworn","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib330","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/978-1-62703-758-7_21","article-title":"Case study 4. Predicting the drug interaction potential for inhibition of CYP2C8 by montelukast","volume":"1113","author":"Korzekwa","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1124\/pr.115.011411_bib331","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.114.058297","article-title":"A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. Application to experimental data","volume":"42","author":"Korzekwa","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib332","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/00498254.2013.837988","article-title":"Risk assessment of drug-drug interactions using hepatocytes suspended in serum during the drug discovery process","volume":"44","author":"Kosugi","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib333","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bcp.2008.05.025","article-title":"The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms","volume":"76","author":"Kot","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib334","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2133\/dmpk.DMPK-12-RG-014","article-title":"Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards","volume":"27","author":"Kozakai","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib335","article-title":"Effect of buffer conditions on CYP2C8-mediated paclitaxel 6\u03b1-hydroxylation and CYP3A4-mediated triazolam \u03b1- and 4-hydroxylation by human liver microsomes","author":"Kudo","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib336","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-2350-10-124","article-title":"Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population","volume":"10","author":"Kudzi","year":"2009","journal-title":"BMC Med Genet"},{"key":"10.1124\/pr.115.011411_bib337","first-page":"110","article-title":"Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001)","volume":"25","author":"Kumar","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib338","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S0022-3565(25)38591-5","article-title":"Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation","volume":"268","author":"Kumar","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib339","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nprot.2009.86","article-title":"Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm","volume":"4","author":"Kumar","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1124\/pr.115.011411_bib340","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/jpet.102.038992","article-title":"Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide","volume":"303","author":"Kumar","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib341","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/004982598238930","article-title":"Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1","volume":"28","author":"Kurata","year":"1998","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib342","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1067\/mcp.2001.115542","article-title":"Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate","volume":"69","author":"Kyrklund","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib343","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0009-9236(03)00052-3","article-title":"Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance","volume":"73","author":"Kyrklund","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib344","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1124\/dmd.115.063610","article-title":"Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites","volume":"43","author":"Lacy","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib345","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2174\/138920009790711832","article-title":"Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms","volume":"10","author":"Lai","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1124\/pr.115.011411_bib346","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00008571-200309000-00005","article-title":"Differential expression and function of CYP2C isoforms in human intestine and liver","volume":"13","author":"L\u00e4pple","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1124\/pr.115.011411_bib347","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1124\/dmd.114.057778","article-title":"The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk","volume":"42","author":"Lawrence","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib348","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.111.043505","article-title":"Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity","volume":"40","author":"Lee","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib349","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/00498250701534877","article-title":"In vitro metabolism of eupatilin by multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes","volume":"37","author":"Lee","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib350","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/00498250701708521","article-title":"Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil","volume":"38","author":"Lee","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib351","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/187231211796904991","article-title":"Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism","volume":"5","author":"Lee","year":"2011","journal-title":"Drug Metab Lett"},{"key":"10.1124\/pr.115.011411_bib352","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2116\/analsci.28.1197","article-title":"High-throughput screening of inhibitory effects of Bo-yang-hwan-o-tang on human cytochrome P450 isoforms in vitro using UPLC\/MS\/MS","volume":"28","author":"Lee","year":"2012","journal-title":"Anal Sci"},{"key":"10.1124\/pr.115.011411_bib36f","doi-asserted-by":"crossref","DOI":"10.2217\/pgs.15.46","article-title":"Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity","author":"Lee","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1124\/pr.115.011411_bib353","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3109\/00498254.2012.693972","article-title":"In vitro metabolism of piperaquine is primarily mediated by CYP3A4","volume":"42","author":"Lee","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib354","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0003-9861(89)90112-4","article-title":"Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8","volume":"269","author":"Leo","year":"1989","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/pr.115.011411_bib355","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/tpj.2010.13","article-title":"Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity","volume":"11","author":"Leskel\u00e4","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/pr.115.011411_bib356","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1872312808666140606101902","article-title":"Application of a higher throughput approach to derive apparent Michaelis-Menten constants of isoform-selective p450-mediated biotransformation reactions in human hepatocytes","volume":"8","author":"Li","year":"2014","journal-title":"Drug Metab Lett"},{"key":"10.1124\/pr.115.011411_bib357","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1124\/dmd.115.065987","article-title":"High-throughput cytochrome P450 cocktail inhibition assay for assessing drug-drug and drug-botanical interactions","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib358","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1124\/dmd.113.056689","article-title":"The contribution of human OCT1, OCT3, and CYP3A4 to nitidine chloride-induced hepatocellular toxicity","volume":"42","author":"Li","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib359","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/dmd.113.054726","article-title":"Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activity","volume":"42","author":"Li","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib360","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/jpet.300.2.399","article-title":"Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate","volume":"300","author":"Li","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib361","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3109\/00498254.2010.512670","article-title":"In vitro assessment of metabolic drug\u2013drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies","volume":"40","author":"Li","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib362","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.2004.02323.x","article-title":"Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects","volume":"59","author":"Lilja","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib363","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications","volume":"35","author":"Lin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib364","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.105.007765","article-title":"Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers","volume":"34","author":"Ling","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib365","first-page":"1379","article-title":"Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes","volume":"25","author":"Linnet","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib366","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1124\/dmd.110.034439","article-title":"Evaluation of the effects of cytochrome P450 nonsynonymous single-nucleotide polymorphisms on tanshinol borneol ester metabolism and inhibition potential","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib367","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1124\/dmd.110.033381","article-title":"Metabolism of tanshinol borneol ester in rat and human liver microsomes","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib36g","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1124\/dmd.113.056119","article-title":"Bedaquiline metabolism: enzymes and novel metabolites","volume":"42","author":"Liu","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib368","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1432-1033.1993.tb17752.x","article-title":"Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10","volume":"213","author":"Lopez Garcia","year":"1993","journal-title":"Eur J Biochem"},{"key":"10.1124\/pr.115.011411_bib369","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2008.07.004","article-title":"Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers","volume":"58","author":"L\u00f3pez-Rodr\u00edguez","year":"2008","journal-title":"Pharmacol Res"},{"key":"10.1124\/pr.115.011411_bib370","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00280-012-1996-6","article-title":"Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential","volume":"71","author":"LoRusso","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"#cr-split#-10.1124\/pr.115.011411_bib371.1","unstructured":"Lu C, Suri A, and Shimoga P (2012) Application of physiologically based pharmacokinetic modeling and simulation for waiver of orteronel drug-drug interaction trials, in 12th European ISS Meeting"},{"key":"#cr-split#-10.1124\/pr.115.011411_bib371.2","unstructured":"Noordwijk, Netherlands (June 17-21, 2012). Available from: http:\/\/issx.confex.com\/issx\/12euro\/webprogram\/Paper27322.html (Accessed June 18, 2015)"},{"key":"10.1124\/pr.115.011411_bib372","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.bbrc.2004.12.116","article-title":"Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes","volume":"327","author":"Lundblad","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.115.011411_bib373","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1124\/dmd.32.5.473","article-title":"Cytochrome P450 2C8 (CYP2C8)-mediated hydroxylation of an endothelin ETA receptor antagonist in human liver microsomes","volume":"32","author":"Ma","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib374","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0959-8049(98)00034-3","article-title":"Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues","volume":"34","author":"Mac\u00e9","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1124\/pr.115.011411_bib375","first-page":"811","article-title":"Evaluation of liposomal curcumin cytochrome p450 metabolism","volume":"30","author":"Mach","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1124\/pr.115.011411_bib376","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/00498250701433054","article-title":"In vitro metabolism of indiplon and an assessment of its drug interaction potential","volume":"37","author":"Madan","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib377","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1124\/dmd.31.4.421","article-title":"Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes","volume":"31","author":"Madan","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib378","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.1070477","article-title":"Vitamin D receptor as an intestinal bile acid sensor","volume":"296","author":"Makishima","year":"2002","journal-title":"Science"},{"key":"10.1124\/pr.115.011411_bib379","doi-asserted-by":"crossref","first-page":"14264","DOI":"10.1021\/bi991195u","article-title":"Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs","volume":"38","author":"Mancy","year":"1999","journal-title":"Biochemistry"},{"key":"10.1124\/pr.115.011411_bib380","doi-asserted-by":"crossref","first-page":"16205","DOI":"10.1021\/bi961950t","article-title":"Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9","volume":"35","author":"Mancy","year":"1996","journal-title":"Biochemistry"},{"key":"10.1124\/pr.115.011411_bib381","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1124\/dmd.107.017269","article-title":"The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver","volume":"35","author":"Mano","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib382","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0006-2952(01)00925-X","article-title":"Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids","volume":"63","author":"Marill","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib383","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0026-895X(24)12706-X","article-title":"Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites","volume":"58","author":"Marill","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.115.011411_bib384","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389200033336900","article-title":"Retinoic acid metabolism and mechanism of action: a review","volume":"4","author":"Marill","year":"2003","journal-title":"Curr Drug Metab"},{"key":"10.1124\/pr.115.011411_bib385","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2125.2004.02183.x","article-title":"The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects","volume":"59","author":"Mart\u00ednez","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib386","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/tpj.2012.10","article-title":"Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes","volume":"13","author":"Martis","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/pr.115.011411_bib387","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/1475-2875-13-420","article-title":"Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations","volume":"13","author":"Marwa","year":"2014","journal-title":"Malar J"},{"key":"10.1124\/pr.115.011411_bib388","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1124\/dmd.110.037986","article-title":"Interaction of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates with human liver microsomal cytochromes P450: comparison with free doxorubicin","volume":"39","author":"Masek","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib389","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0090-9556(24)15034-9","article-title":"Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research","volume":"27","author":"Masimirembwa","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib390","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/dmd.107.019232","article-title":"Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo","volume":"36","author":"McClue","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib391","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0006-2952(97)00516-9","article-title":"Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain","volume":"55","author":"McFayden","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib392","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/bioinformatics\/btq330","article-title":"Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor","volume":"26","author":"McLaren","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1124\/pr.115.011411_bib393","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.011411_bib394","doi-asserted-by":"crossref","first-page":"15379","DOI":"10.1021\/bi0489309","article-title":"Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants","volume":"43","author":"Melet","year":"2004","journal-title":"Biochemistry"},{"key":"10.1124\/pr.115.011411_bib395","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2015.01.026","article-title":"Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir, and dasabuvir","volume":"63","author":"Menon","year":"2015","journal-title":"J Hepatol"},{"key":"10.1124\/pr.115.011411_bib396","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1749-6632.2000.tb06864.x","article-title":"Fluorometric high-throughput screening for inhibitors of cytochrome P450","volume":"919","author":"Miller","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/pr.115.011411_bib397","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00008571-200004000-00008","article-title":"Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes","volume":"10","author":"Miners","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1124\/pr.115.011411_bib398","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.4238\/2013.July.8.7","article-title":"Prevalence of CYP2C8 polymorphisms in a North Indian population","volume":"12","author":"Minhas","year":"2013","journal-title":"Genet Mol Res"},{"key":"10.1124\/pr.115.011411_bib399","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2133\/dmpk.DMPK-12-RG-101","article-title":"Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes","volume":"28","author":"Misaka","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib400","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/tx0155350","article-title":"Sex differences in the metabolism of (+)- and (-)-limonene enantiomers to carveol and perillyl alcohol derivatives by cytochrome p450 enzymes in rat liver microsomes","volume":"15","author":"Miyazawa","year":"2002","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/pr.115.011411_bib401","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF03190868","article-title":"In vitro metabolism of perospirone in rat, monkey and human liver microsomes","volume":"28","author":"Mizuno","year":"2003","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib402","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1345\/aph.1G347","article-title":"Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism","volume":"40","author":"Moller","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1124\/pr.115.011411_bib403","first-page":"125","article-title":"Biotransformation of taxoids by human cytochromes P450: structure-activity relationship","volume":"84","author":"Monsarrat","year":"1997","journal-title":"Bull Cancer"},{"key":"10.1124\/pr.115.011411_bib404","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/abio.2002.5673","article-title":"A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies","volume":"306","author":"Moody","year":"2002","journal-title":"Anal Biochem"},{"key":"10.1124\/pr.115.011411_bib405","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/00498250601146962","article-title":"Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes","volume":"37","author":"Moon","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib406","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1124\/dmd.30.3.301","article-title":"Phosphonate O-deethylation of [4-(4-bromo-2-cyano-phenylcarbamoyl) benzyl]-phosphonic acid diethyl ester, a lipoprotein lipase-promoting agent, catalyzed by cytochrome P450 2C8 and 3A4 in human liver microsomes","volume":"30","author":"Morioka","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib407","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0378-4347(00)83483-0","article-title":"Sensitive analysis of blood for amodiaquine and three metabolites by high-performance liquid chromatography with electrochemical detection","volume":"383","author":"Mount","year":"1986","journal-title":"J Chromatogr A"},{"key":"10.1124\/pr.115.011411_bib408","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1248\/bpb.b14-00366","article-title":"Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro","volume":"37","author":"Mukai","year":"2014","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/pr.115.011411_bib409","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108386","article-title":"Modulation of cytochrome P450 metabolism and transport across intestinal epithelial barrier by ginger biophenolics","volume":"9","author":"Mukkavilli","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/pr.115.011411_bib410","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/00498250801956350","article-title":"In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition","volume":"38","author":"Mukoyoshi","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib411","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/hmg\/ddr543","article-title":"Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites","volume":"21","author":"M\u00fcrdter","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1124\/pr.115.011411_bib412","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1742-7843.2009.00457.x","article-title":"The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro","volume":"105","author":"Muschler","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib413","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2710.2005.00653.x","article-title":"Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians","volume":"30","author":"Muthiah","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"10.1124\/pr.115.011411_bib414","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/j.2042-7158.2012.01551.x","article-title":"In-vitro inhibitory effect of Tualang honey on cytochrome P450 2C8 activity","volume":"64","author":"Muthiah","year":"2012","journal-title":"J Pharm Pharmacol"},{"issue":"Suppl 1","key":"10.1124\/pr.115.011411_bib415","first-page":"15","article-title":"Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions","volume":"56","author":"M\u00fcck","year":"1998","journal-title":"Drugs"},{"key":"10.1124\/pr.115.011411_bib416","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003088-200039020-00002","article-title":"Clinical pharmacokinetics of cerivastatin","volume":"39","author":"M\u00fcck","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib417","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s002280050408","article-title":"Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin","volume":"53","author":"M\u00fcck","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib418","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0006-2952(99)00192-6","article-title":"Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes","volume":"58","author":"Nadin","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib419","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2125.2012.04182.x","article-title":"The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate","volume":"74","author":"Naik","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib420","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/00498250601188808","article-title":"Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans","volume":"37","author":"Nakagomi-Hagihara","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib421","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1124\/dmd.31.6.687","article-title":"Genetic polymorphisms of CYP2C8 in Japanese population","volume":"31","author":"Nakajima","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib422","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1248\/bpb.28.882","article-title":"Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes","volume":"28","author":"Nakamura","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/pr.115.011411_bib423","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1124\/dmd.109.031542","article-title":"Human liver expression of CYP2C8: gender, age, and genotype effects","volume":"38","author":"Naraharisetti","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib424","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.bcp.2006.01.015","article-title":"Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes","volume":"71","author":"Narimatsu","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib425","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1124\/dmd.109.027516","article-title":"An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes","volume":"37","author":"Nassar","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib426","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","article-title":"Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes","volume":"161","author":"Nebot","year":"2010","journal-title":"Br J Pharmacol"},{"key":"#cr-split#-10.1124\/pr.115.011411_bib427.1","unstructured":"Negishi I, Tsuda-Tsukimoto M, Kozakai K, and Kume T (2007) Utility of cryopreserved human hepatocytes for assessment of mechanism-based inactivation, in 8th International ISXX Meeting"},{"key":"#cr-split#-10.1124\/pr.115.011411_bib427.2","unstructured":"Sendai, Japan (October 9-12, 2007). Available from: http:\/\/issx.confex.com\/issx\/intl8\/webprogram\/Paper6588.html (Accessed June 18, 2015)"},{"key":"10.1124\/pr.115.011411_bib428","first-page":"323","article-title":"Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics","volume":"11","author":"Neuvonen","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/pr.115.011411_bib429","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1742-7843.2012.00858.x","article-title":"Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee","volume":"110","author":"Neuvonen","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib430","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib431","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jcph.510","article-title":"Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK","volume":"55","author":"Nguyen","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib432","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1124\/dmd.112.045328","article-title":"Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects","volume":"40","author":"Nicolas","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib433","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00125-003-1181-x","article-title":"Gemfibrozil considerably increases the plasma concentrations of rosiglitazone","volume":"46","author":"Niemi","year":"2003","journal-title":"Diabetologia"},{"key":"10.1124\/pr.115.011411_bib434","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2125.2005.02385.x","article-title":"Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide","volume":"60","author":"Niemi","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib435","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2005.01.018","article-title":"Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics","volume":"77","author":"Niemi","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib436","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00125-003-1034-7","article-title":"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide","volume":"46","author":"Niemi","year":"2003","journal-title":"Diabetologia"},{"key":"10.1124\/pr.115.011411_bib437","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1067\/mcp.2000.111183","article-title":"Rifampin decreases the plasma concentrations and effects of repaglinide","volume":"68","author":"Niemi","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib438","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.clpt.2004.05.001","article-title":"Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone","volume":"76","author":"Niemi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib439","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2125.2003.02027.x","article-title":"The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects","volume":"57","author":"Niemi","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib440","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0009-9236(03)00228-5","article-title":"Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide","volume":"74","author":"Niemi","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib441","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0009-9236(01)84578-1","article-title":"Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride","volume":"70","author":"Niemi","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib442","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.115.011411_bib443","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00228-006-0133-z","article-title":"Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide","volume":"62","author":"Niemi","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib444","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/00498254.2013.819594","article-title":"Identification of a suitable and selective inhibitor towards aldehyde oxidase catalyzed reactions","volume":"44","author":"Nirogi","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib445","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/00498254.2014.945196","article-title":"Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays","volume":"45","author":"Nirogi","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib446","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/dmd.111.040105","article-title":"An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide","volume":"40","author":"Nishihara","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib447","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1248\/yakushi.123.369","article-title":"Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR","volume":"123","author":"Nishimura","year":"2003","journal-title":"Yakugaku Zasshi"},{"key":"10.1124\/pr.115.011411_bib448","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1248\/yakushi.122.339","article-title":"Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR","volume":"122","author":"Nishimura","year":"2002","journal-title":"Yakugaku Zasshi"},{"key":"10.1124\/pr.115.011411_bib449","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3109\/00498250903191427","article-title":"Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel","volume":"39","author":"Nishiya","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib450","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/004982599238731","article-title":"Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine","volume":"29","author":"Niwa","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib451","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1248\/bpb.23.498","article-title":"Inhibition of drug-metabolizing enzyme activity in human hepatic cytochrome P450s by bisphenol A","volume":"23","author":"Niwa","year":"2000","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/pr.115.011411_bib452","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-3565(24)39043-3","article-title":"Inhibition of human cytochrome P450 enzymes by constituents of St. John\u2019s Wort, an herbal preparation used in the treatment of depression","volume":"294","author":"Obach","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib453","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib454","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/dmd.106.012344","article-title":"The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting","volume":"35","author":"O\u2019Donnell","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib455","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.105.007633","article-title":"Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions","volume":"34","author":"Ogilvie","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib456","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/dmd.111.042259","article-title":"Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities","volume":"40","author":"Ohtsuki","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib457","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0090-9556(24)15077-5","article-title":"A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor","volume":"28","author":"Ohyama","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib458","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2125.2000.00298.x","article-title":"Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine","volume":"50","author":"Olesen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib460","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2125.2000.00316.x","article-title":"The xenobiotic inhibitor profile of cytochrome P4502C8","volume":"50","author":"Ong","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib461","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.meegid.2014.08.011","article-title":"Absence of the human CYP2C8*3 allele in Ugandan children exposed to Plasmodium falciparum malaria","volume":"27","author":"Paganotti","year":"2014","journal-title":"Infect Genet Evol"},{"key":"10.1124\/pr.115.011411_bib462","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/infdis\/jir629","article-title":"Human genetic variation is associated with Plasmodium falciparum drug resistance","volume":"204","author":"Paganotti","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.115.011411_bib463","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1475-2875-11-125","article-title":"Distribution of human CYP2C8*2 allele in three different African populations","volume":"11","author":"Paganotti","year":"2012","journal-title":"Malar J"},{"key":"10.1124\/pr.115.011411_bib464","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jep.2012.07.024","article-title":"Inhibitory effects of cytochrome P450 enzymes CYP2C8, CYP2C9, CYP2C19 and CYP3A4 by Labisia pumila extracts","volume":"143","author":"Pan","year":"2012","journal-title":"J Ethnopharmacol"},{"key":"10.1124\/pr.115.011411_bib465","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11418-013-0794-8","article-title":"Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro","volume":"68","author":"Pan","year":"2014","journal-title":"J Nat Med"},{"key":"10.1124\/pr.115.011411_bib466","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00210-012-0731-5","article-title":"In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8)","volume":"385","author":"Pang","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pr.115.011411_bib467","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.clpt.6100122","article-title":"Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa","volume":"82","author":"Parikh","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib468","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.109.028274","article-title":"In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran","volume":"37","author":"Paris","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib469","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clpt.2003.10.003","article-title":"Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects","volume":"75","author":"Park","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib470","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1124\/dmd.104.000802","article-title":"Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin","volume":"33","author":"Parte","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib36h","first-page":"1548","article-title":"Cytochrome P450 involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms","volume":"29","author":"Pearce","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib471","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1089\/gtmb.2011.0275","article-title":"Genetic polymorphisms of CYP2C8 in the Czech Republic","volume":"16","author":"Pechandova","year":"2012","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1124\/pr.115.011411_bib472","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bcpt.12429","article-title":"Drug Metabolism - From In Vitro to In Vivo, From Simple to Complex: Reflections of the BCPT Nordic Prize 2014 Awardee","volume":"117","author":"Pelkonen","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib473","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/00498250110055479","article-title":"Carbamazepine: a \u2018blind\u2019 assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems","volume":"31","author":"Pelkonen","year":"2001","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib474","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00204-008-0332-8","article-title":"Inhibition and induction of human cytochrome P450 enzymes: current status","volume":"82","author":"Pelkonen","year":"2008","journal-title":"Arch Toxicol"},{"key":"10.1124\/pr.115.011411_bib36i","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3109\/00498254.2015.1036954","article-title":"A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC\/MS\/MS run to support reliable in vitro inhibitory drug-drug interaction evaluation","volume":"45","author":"Peng","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib475","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2125.2006.02615.x","article-title":"Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients","volume":"62","author":"Perez-Ruixo","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib476","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00498250802638155","article-title":"Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design","volume":"39","author":"Perloff","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib477","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0026-895X(25)08555-4","article-title":"Oxidative metabolism of lansoprazole by human liver cytochromes P450","volume":"47","author":"Pichard","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.115.011411_bib478","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1124\/dmd.105.003681","article-title":"In vitro metabolism study of buprenorphine: evidence for new metabolic pathways","volume":"33","author":"Picard","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib479","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/TP.0b013e31820ae4ac","article-title":"CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients","volume":"91","author":"Picard","year":"2011","journal-title":"Transplantation"},{"key":"10.1124\/pr.115.011411_bib480","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.09.2008.0994","article-title":"The impact of tuberculosis treatment on glycaemic control and the significant response to rosiglitazone","volume":"2009","author":"Pimazoni","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1124\/pr.115.011411_bib481","unstructured":"PMDA (2014) Japanese Pharmaceuticals and Medical Devices Agency, review report: Acofide. Available from: http:\/\/www.pmda.go.jp\/files\/000153467.pdf (Accessed September 15, 2015)"},{"key":"10.1124\/pr.115.011411_bib482","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1124\/jpet.104.071803","article-title":"Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro","volume":"311","author":"Polasek","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib483","doi-asserted-by":"crossref","first-page":"33698","DOI":"10.1074\/jbc.M805999200","article-title":"Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates","volume":"283","author":"Porubsky","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.011411_bib484","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1124\/dmd.108.022897","volume":"36","author":"Prakash","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib485","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1124\/dmd.31.6.748","article-title":"In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation","volume":"31","author":"Projean","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib486","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/0049825031000121608","article-title":"Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes","volume":"33","author":"Projean","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib487","first-page":"1191","article-title":"In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s","volume":"25","author":"Prueksaritanont","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib488","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/004982500237811","article-title":"Interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase in hepatic metabolism of L-775,606, a potent 5-HT(1D) receptor agonist","volume":"30","author":"Prueksaritanont","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib489","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1365-2125.2003.01833.x","article-title":"The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6","volume":"56","author":"Prueksaritanont","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib490","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11095-004-9011-5","article-title":"Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes","volume":"22","author":"Prueksaritanont","year":"2005","journal-title":"Pharm Res"},{"key":"10.1124\/pr.115.011411_bib491","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"#cr-split#-10.1124\/pr.115.011411_bib492.1","unstructured":"Pusalkar S, Zhou X, Li Y, Liao M, Yang J, Chong S, Venkatakrishnan K, and Chowdhury S (2014) Absorption, metabolism, and excretion of alisertib (MLN8237), an aurora A kinase inhibitor, in patients with advanced solid tumors or lymphomas, in 19th North American ISSX\/29th JSSX Meeting"},{"key":"#cr-split#-10.1124\/pr.115.011411_bib492.2","unstructured":"San Francisco, CA (October 19-23, 2014). Available from: http:\/\/issx.confex.com\/issx\/19NA\/webprogrampreliminary\/Paper34303.html (Accessed August 26, 2015)"},{"key":"10.1124\/pr.115.011411_bib493","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.fct.2013.02.054","article-title":"Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes","volume":"56","author":"Qi","year":"2013","journal-title":"Food Chem Toxicol"},{"key":"10.1124\/pr.115.011411_bib494","first-page":"216","article-title":"Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol","volume":"66","author":"Qu","year":"2011","journal-title":"Pharmazie"},{"key":"10.1124\/pr.115.011411_bib495","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2133\/dmpk.DMPK-11-RG-048","article-title":"Inhibition of cytochrome P450 2C8-mediated drug metabolism by the flavonoid diosmetin","volume":"26","author":"Quintieri","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib496","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3565(24)29202-8","article-title":"Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays","volume":"299","author":"Rae","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib497","first-page":"5543","article-title":"Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8","volume":"54","author":"Rahman","year":"1994","journal-title":"Cancer Res"},{"key":"10.1124\/pr.115.011411_bib498","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/dmd.109.030387","article-title":"Hepatocyte nuclear factor 4alpha regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes","volume":"38","author":"Rana","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib499","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/jpet.102.033837","article-title":"Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes","volume":"302","author":"Raucy","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib500","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0022-3565(25)13368-5","article-title":"Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily","volume":"252","author":"Relling","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib501","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00008571-199402000-00005","article-title":"Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9","volume":"4","author":"Rettie","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1124\/pr.115.011411_bib502","doi-asserted-by":"crossref","first-page":"512","DOI":"10.5414\/CPP42512","article-title":"Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil","volume":"42","author":"Reyderman","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib503","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0003-9861(95)90023-3","article-title":"Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes","volume":"320","author":"Rifkind","year":"1995","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/pr.115.011411_bib504","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1124\/dmd.106.010835","article-title":"The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole","volume":"35","author":"Robert","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib505","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/bdd.598","article-title":"In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1","volume":"29","author":"Rochat","year":"2008","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.115.011411_bib506","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fgene.2012.00229","article-title":"Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations","volume":"3","author":"Roco","year":"2012","journal-title":"Front Genet"},{"key":"10.1124\/pr.115.011411_bib507","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0090-9556(25)07254-X","article-title":"[O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9\/10","volume":"24","author":"Rodrigues","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"#cr-split#-10.1124\/pr.115.011411_bib508.1","unstructured":"Rong H, Maclin D, Yao L, Lin J, Yin D, and Xu H (2008) Mechanism-based inhibition of human liver microsomal cytochrome P450 3A by a focal adhesion kinase (FAK) inhibitor PF-562,27, in 2nd Asian Pacific ISSX Meeting"},{"key":"#cr-split#-10.1124\/pr.115.011411_bib508.2","unstructured":"Shanghai, China (May 11-13, 2008). Available from: http:\/\/issx.confex.com\/issx\/ap08\/webprogram\/start.html (Accessed August 25, 2015)"},{"key":"10.1124\/pr.115.011411_bib509","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","article-title":"Simulation and prediction of in vivo drug metabolism in human populations from in vitro data","volume":"6","author":"Rostami-Hodjegan","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pr.115.011411_bib510","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1345\/aph.1M597","article-title":"Symptomatic hypoglycemia associated with trimethoprim\/sulfamethoxazole and repaglinide in a diabetic patient","volume":"44","author":"Roustit","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1124\/pr.115.011411_bib511","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1124\/dmd.109.030866","article-title":"Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation","volume":"38","author":"Rowbotham","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib512","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-3156.2005.01525.x","article-title":"Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana","volume":"10","author":"R\u00f6wer","year":"2005","journal-title":"Trop Med Int Health"},{"key":"10.1124\/pr.115.011411_bib513","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1074\/jbc.M511232200","article-title":"Crystal structure of human cytochrome P450 2D6","volume":"281","author":"Rowland","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.011411_bib514","first-page":"687","article-title":"Abundance of cytochromes P450 in human liver: a meta-analysis","volume":"57","author":"Rowland Yeo","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib515","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/dmd.31.4.439","article-title":"Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition","volume":"31","author":"Sahi","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib516","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/004982500237541","article-title":"Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450","volume":"30","author":"Sai","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib517","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11095-005-9371-5","article-title":"Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport","volume":"23","author":"Sakaeda","year":"2006","journal-title":"Pharm Res"},{"key":"10.1124\/pr.115.011411_bib518","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.112.045286","article-title":"A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance","volume":"40","author":"S\u00e4ll","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib519","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.phymed.2010.08.012","article-title":"Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids","volume":"18","author":"Salminen","year":"2011","journal-title":"Phytomedicine"},{"key":"10.1124\/pr.115.011411_bib520","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1124\/dmd.31.9.1093","article-title":"Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems","volume":"31","author":"Salonen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib680","article-title":"Contribution of major metabolites towards complex drug-drug interactions of deleobuvir: in vitro predictions and in vivo outcomes","author":"Sane","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib521","doi-asserted-by":"crossref","first-page":"14348","DOI":"10.1074\/jbc.M611692200","article-title":"Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2","volume":"282","author":"Sansen","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.011411_bib522","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis","volume":"112","author":"Sarasquete","year":"2008","journal-title":"Blood"},{"key":"10.1124\/pr.115.011411_bib523","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bcp.12353","article-title":"Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins","volume":"78","author":"Schelleman","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib524","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib525","doi-asserted-by":"crossref","first-page":"17227","DOI":"10.1074\/jbc.M802180200","article-title":"Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid","volume":"283","author":"Schoch","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.011411_bib526","doi-asserted-by":"crossref","first-page":"9497","DOI":"10.1074\/jbc.M312516200","article-title":"Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site","volume":"279","author":"Schoch","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.011411_bib527","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1067\/mcp.2002.129321","article-title":"Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance","volume":"72","author":"Scordo","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib528","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1755-5922.2009.00104.x","article-title":"Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone","volume":"27","author":"Schwartz","year":"2009","journal-title":"Cardiovasc Ther"},{"key":"10.1124\/pr.115.011411_bib529","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/00498251003592683","article-title":"Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail","volume":"40","author":"Sevior","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib700","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pharmthera.2014.05.011","article-title":"Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders","volume":"144","author":"Shahabi","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib530","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1248\/bpb.b15-00313","article-title":"Inhibitory Potential of Twenty Five Anti-tuberculosis Drugs on CYP Activities in Human Liver Microsomes","volume":"38","author":"Shimokawa","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/pr.115.011411_bib531","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.104.068536","volume":"311","author":"Shitara","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib532","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40262-015-0255-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan","volume":"54","author":"Sidharta","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib533","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.fct.2015.04.024","article-title":"In vitro inhibition of human cytochrome P450 by cudratricusxanthone A","volume":"81","author":"Sim","year":"2015","journal-title":"Food Chem Toxicol"},{"key":"10.1124\/pr.115.011411_bib534","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.011411_bib535","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2133\/dmpk.23.165","article-title":"Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity","volume":"23","author":"Singh","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib536","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1124\/dmd.112.047373","article-title":"Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation","volume":"40","author":"Sj\u00f6gren","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib537","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0091270009340418","article-title":"Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers","volume":"50","author":"Skerjanec","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib538","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/0091270003255921","article-title":"Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development","volume":"43","author":"Smith","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib539","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/tx034033e","article-title":"Mechanisms of troglitazone hepatotoxicity","volume":"16","author":"Smith","year":"2003","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/pr.115.011411_bib540","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4062\/biomolther.2013.107","article-title":"A Comparison of the In Vitro Inhibitory Effects of Thelephoric Acid and SKF-525A on Human Cytochrome P450 Activity","volume":"22","author":"Song","year":"2014","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1124\/pr.115.011411_bib541","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s12272-013-0281-5","article-title":"In vitro inhibitory effect of piperlonguminine isolated from Piper longum on human cytochrome P450 1A2","volume":"37","author":"Song","year":"2014","journal-title":"Arch Pharm Res"},{"key":"10.1124\/pr.115.011411_bib542","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(25)12102-2","article-title":"Variability in human cytochrome P450 paclitaxel metabolism","volume":"275","author":"Sonnichsen","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib543","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1034\/j.1600-0773.2002.910404.x","article-title":"Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A","volume":"91","author":"Soyama","year":"2002","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib544","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1248\/bpb.24.1427","article-title":"Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism","volume":"24","author":"Soyama","year":"2001","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/pr.115.011411_bib545","first-page":"275","article-title":"Effects of concurrent administration of efavirenz on the disposition kinetics of amodiaquine in healthy volunteers","volume":"6","author":"Soyinka","year":"2013","journal-title":"J Pharm Res"},{"key":"10.1124\/pr.115.011411_bib546","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/tpj.2009.10","article-title":"Global variation in CYP2C8-CYP2C9 functional haplotypes","volume":"9","author":"Speed","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/pr.115.011411_bib547","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0003-9861(92)90404-K","article-title":"17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA","volume":"293","author":"Spink","year":"1992","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/pr.115.011411_bib548","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0960-0760(94)90037-X","article-title":"The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 beta-estradiol 4-hydroxylase","volume":"51","author":"Spink","year":"1994","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/pr.115.011411_bib549","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0026-895X(25)12858-7","article-title":"Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4\u2032-hydroxylase cytochrome P-450 enzymes","volume":"40","author":"Srivastava","year":"1991","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.115.011411_bib550","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1128\/AAC.01700-12","article-title":"Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania","volume":"57","author":"Staehli Hodel","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.115.011411_bib551","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.011411_bib552","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/FPC.0b013e32835f91fc","article-title":"The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPAR\u03b3 on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes","volume":"23","author":"Stage","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/pr.115.011411_bib553","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S0026-895X(24)12045-7","article-title":"Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4","volume":"28","author":"St\u00f6rmer","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib554","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/tpj.2010.89","article-title":"Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians","volume":"12","author":"Suarez-Kurtz","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/pr.115.011411_bib555","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3324\/haematol.2011.042572","article-title":"CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"10.1124\/pr.115.011411_bib556","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ptr.3189","article-title":"Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside","volume":"24","author":"Sun","year":"2010","journal-title":"Phytother Res"},{"key":"10.1124\/pr.115.011411_bib557","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jcph.437","article-title":"Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib","volume":"55","author":"Suttle","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib558","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0022-3565(24)36788-6","article-title":"Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites","volume":"282","author":"Sutton","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.115.011411_bib559","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0090-9556(24)14926-4","article-title":"Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate","volume":"27","author":"Suzuki","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib560","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/87912","article-title":"The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux","volume":"7","author":"Synold","year":"2001","journal-title":"Nat Med"},{"key":"10.1124\/pr.115.011411_bib561","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1124\/dmd.105.004903","volume":"33","author":"Tachibana","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib562","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/FPC.0b013e3283620c3b","article-title":"OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis","volume":"23","author":"Tamraz","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/pr.115.011411_bib563","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1038\/bjc.2014.233","article-title":"Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies","volume":"110","author":"Tan","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1124\/pr.115.011411_bib564","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cpt.101","article-title":"Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans","volume":"97","author":"Tarkiainen","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib565","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1124\/mol.110.065839","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib","volume":"78","author":"Teng","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.115.011411_bib36k","unstructured":"TGA (2014) Australian Public Assessment Report for Crizotinib. Available from: https:\/\/www.tga.gov.au\/file\/882\/download (Accessed September, 2015)"},{"key":"10.1124\/pr.115.011411_bib566","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.bcp.2010.05.023","article-title":"The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid","volume":"80","author":"Thatcher","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib567","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1124\/mol.114.097402","article-title":"Activating and Inhibitory Functions of WNT\/\u03b2-Catenin in the Induction of Cytochromes P450 by Nuclear Receptors in HepaRG Cells","volume":"87","author":"Thomas","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.115.011411_bib568","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0140-6736(00)99016-0","article-title":"Gene expression in distinct regions of the heart","volume":"355","author":"Thum","year":"2000","journal-title":"Lancet"},{"key":"10.1124\/pr.115.011411_bib569","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1124\/dmd.110.036921","article-title":"Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide","volume":"39","author":"Tomalik-Scharte","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib570","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/clpt.2014.141","article-title":"Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions","volume":"96","author":"Tornio","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib571","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00228-006-0155-6","article-title":"The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone","volume":"62","author":"Tornio","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib572","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/clpt.2008.34","article-title":"The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo","volume":"84","author":"Tornio","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib573","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00228-007-0273-9","article-title":"Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen","volume":"63","author":"Tornio","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib574","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/dmd.107.018010","article-title":"Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone","volume":"36","author":"Tornio","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib575","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1742-7843.2005.pto_134.x","article-title":"Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8","volume":"97","author":"Tornio","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib576","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clpt.2004.12.267","article-title":"Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance","volume":"77","author":"Totah","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib577","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/00498250410001691280","article-title":"Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man","volume":"34","author":"Tougou","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib578","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2125.1999.00923.x","article-title":"Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil","volume":"47","author":"Tracy","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib579","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s002280050293","article-title":"Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation","volume":"52","author":"Tracy","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib580","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00008571-199712000-00002","article-title":"Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo\/in-vitro correlation and inducibility","volume":"7","author":"Treluyer","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1124\/pr.115.011411_bib581","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1124\/dmd.114.059675","article-title":"Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometry","volume":"42","author":"Tse","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib582","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejps.2004.10.006","article-title":"Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay","volume":"24","author":"Turpeinen","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/pr.115.011411_bib583","doi-asserted-by":"crossref","first-page":"14064","DOI":"10.3390\/ijms140714064","article-title":"Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo","volume":"14","author":"Turpeinen","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1124\/pr.115.011411_bib584","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2174\/1381612013397708","article-title":"The role of metabolism and toxicokinetics in retinoid teratogenesis","volume":"7","author":"Tzimas","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1124\/pr.115.011411_bib585","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00228-004-0740-5","article-title":"Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro","volume":"60","author":"Ufer","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib586","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/rcm.1621","article-title":"Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography\/mass spectrometry and automated online extraction","volume":"18","author":"Unger","year":"2004","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/pr.115.011411_bib587","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s00210-003-0781-9","article-title":"Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants","volume":"368","author":"V\u00e1clav\u00edkov\u00e1","year":"2003","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pr.115.011411_bib588","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-9556(25)06589-4","article-title":"Taxol metabolism and disposition in cancer patients","volume":"23","author":"Walle","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib589","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1124\/dmd.112.050716","article-title":"Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects","volume":"41","author":"Walles","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib590","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/0091270004270642","article-title":"Examination of 209 drugs for inhibition of cytochrome P450 2C8","volume":"45","author":"Walsky","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib591","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib592","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.104.002766","article-title":"Selective inhibition of human cytochrome P4502C8 by montelukast","volume":"33","author":"Walsky","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib593","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1124\/dmd.112.045302","article-title":"Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs","volume":"40","author":"Walsky","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib594","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1124\/mol.112.080739","article-title":"Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation","volume":"82","author":"VandenBrink","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.115.011411_bib595","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.111.039065","article-title":"Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate","volume":"39","author":"VandenBrink","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib596","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1124\/dmd.104.000182","article-title":"The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol","volume":"32","author":"Wang","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib597","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1124\/dmd.31.6.742","article-title":"Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro","volume":"31","author":"Wang","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib598","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1124\/dmd.30.12.1352","article-title":"Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes","volume":"30","author":"Wang","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib599","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1124\/dmd.106.010587","article-title":"CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]","volume":"34","author":"Wang","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib600","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/dmd.113.053793","article-title":"Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials","volume":"42","author":"Wang","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib601","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/chir.22289","article-title":"Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine","volume":"26","author":"Wang","year":"2014","journal-title":"Chirality"},{"key":"10.1124\/pr.115.011411_bib602","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1742-7843.2011.00807.x","article-title":"Distribution of CYP2C polymorphisms in an Amerindian population of Brazil","volume":"110","author":"Vargens","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.115.011411_bib603","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1124\/dmd.115.064303","article-title":"Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-\u03b2-Glucuronide","volume":"43","author":"Varma","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib604","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1124\/dmd.112.050583","article-title":"Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin","volume":"41","author":"Varma","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib605","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1208\/s12248-014-9614-7","article-title":"Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide","volume":"16","author":"Varma","year":"2014","journal-title":"AAPS J"},{"key":"10.1124\/pr.115.011411_bib606","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.lfs.2006.12.032","article-title":"Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes","volume":"80","author":"Watanabe","year":"2007","journal-title":"Life Sci"},{"key":"10.1124\/pr.115.011411_bib607","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00228-011-1001-z","article-title":"In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6\u03b1-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance","volume":"67","author":"Wattanachai","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib608","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0003-9861(91)90602-F","article-title":"Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s","volume":"290","author":"Waxman","year":"1991","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/pr.115.011411_bib609","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clpt.2004.12.173","article-title":"In vitro studies and computer simulation of interactions between R483, a novel thiazolidinedione, and cytochrome P450 substrates","volume":"77","author":"Weber","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib610","first-page":"1359","article-title":"Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9","volume":"29","author":"Wen","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib611","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/dmd.30.6.631","article-title":"Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively","volume":"30","author":"Wen","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib612","doi-asserted-by":"crossref","first-page":"17333","DOI":"10.1016\/S0021-9258(18)41930-8","article-title":"Transcriptional regulatory elements for basal expression of cytochrome P450IIC genes","volume":"267","author":"Venepally","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.011411_bib613","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1177\/00912700122012634","article-title":"Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies","volume":"41","author":"Venkatakrishnan","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib614","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1124\/dmd.111.038315","article-title":"In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification","volume":"39","author":"Ventura","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib615","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.bcp.2009.02.020","article-title":"In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping","volume":"77","author":"Vermeir","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib616","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1042\/bj2890533","article-title":"Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily","volume":"289","author":"Veronese","year":"1993","journal-title":"Biochem J"},{"key":"10.1124\/pr.115.011411_bib617","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/0091270010366446","article-title":"Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin","volume":"51","author":"Whitfield","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1124\/pr.115.011411_bib618","first-page":"T3408","article-title":"Identification of the cytochrome P450 isoforms responsible for the hydroxylation of Brivaracetam, in AAPS Annual Meeting and Exposition, San Diego, California (November 12-16, 2007)","volume":"9","author":"Whomsley","year":"2007","journal-title":"AAPS J"},{"key":"10.1124\/pr.115.011411_bib619","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s11033-013-2971-y","article-title":"Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study","volume":"41","author":"Vicente","year":"2014","journal-title":"Mol Biol Rep"},{"key":"10.1124\/pr.115.011411_bib620","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0090-9556(24)15022-2","article-title":"Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions","volume":"27","author":"Vickers","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib621","first-page":"1269","article-title":"In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions","volume":"29","author":"Vickers","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib622","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/dmd.106.013136","article-title":"Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans","volume":"35","author":"Vincent","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib623","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature01862","article-title":"Crystal structure of human cytochrome P450 2C9 with bound warfarin","volume":"424","author":"Williams","year":"2003","journal-title":"Nature"},{"key":"10.1124\/pr.115.011411_bib624","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/dmd.104.002998","article-title":"Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism","volume":"33","author":"Winter","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib625","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0090-9556(24)15155-0","article-title":"CYP2C8\/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone","volume":"28","author":"Winter","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib626","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3109\/00498250903180289","article-title":"Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor","volume":"39","author":"Wong","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib627","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/gtmb.2012.0256","article-title":"CYP2C8 polymorphism frequencies among Han, Uighur, Hui, and Mongolian Chinese populations","volume":"17","author":"Wu","year":"2013","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1124\/pr.115.011411_bib628","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1124\/dmd.114.060095","article-title":"In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent","volume":"42","author":"Wu","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib629","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2174\/15680266113136660157","article-title":"Cytochrome P450 2C8 and drug metabolism","volume":"13","author":"Xiaoping","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/pr.115.011411_bib630","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2133\/dmpk.DMPK-12-RG-124","article-title":"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19","volume":"28","author":"Xu","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib631","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1124\/dmd.113.056804","article-title":"Evaluation of 23 lots of commercially available cryopreserved hepatocytes for induction assays of human cytochromes P450","volume":"42","author":"Yajima","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib632","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2133\/dmpk.17.437","article-title":"Application of microtiter plate assay to evaluate inhibitory effects of various compounds on nine cytochrome P450 isoforms and to estimate their inhibition patterns","volume":"17","author":"Yamamoto","year":"2002","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.115.011411_bib633","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002040050588","article-title":"Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes","volume":"73","author":"Yamazaki","year":"1999","journal-title":"Arch Toxicol"},{"key":"10.1124\/pr.115.011411_bib634","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0090-9556(24)14927-6","article-title":"Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes","volume":"27","author":"Yamazaki","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib635","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/004982599238632","article-title":"Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes","volume":"29","author":"Yamazaki","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib636","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/004982500237820","article-title":"In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone","volume":"30","author":"Yamazaki","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib637","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/00498250500136676","article-title":"Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport","volume":"35","author":"Yamazaki","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib638","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2125.2011.04076.x","article-title":"Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes","volume":"73","author":"Yang","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.115.011411_bib639","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/pr.115.011411_bib640","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0006-2952(97)00558-3","article-title":"Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam","volume":"55","author":"Yang","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib641","doi-asserted-by":"crossref","first-page":"38091","DOI":"10.1074\/jbc.C400293200","article-title":"The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution","volume":"279","author":"Yano","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.011411_bib642","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0006-291X(02)02592-5","article-title":"Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms","volume":"299","author":"Yasar","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.115.011411_bib643","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/00498254.2010.524950","article-title":"Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine","volume":"41","author":"Ye","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib644","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/dmd.110.035899","article-title":"Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo","volume":"39","author":"Yeo","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib645","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.109.030841","article-title":"Disposition and metabolism of semagacestat, a gamma-secretase inhibitor, in humans","volume":"38","author":"Yi","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib646","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/clpt.2011.351","article-title":"Transporter-mediated drug\u2013drug interactions involving OATP substrates: predictions based on in vitro inhibition studies","volume":"91","author":"Yoshida","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.115.011411_bib647","article-title":"Metabolism of BYZX in human liver microsomes and cytosol: identification of the metabolites and metabolic pathways of BYZX","volume":"8","author":"Yu","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/pr.115.011411_bib648","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/bdd.1842","article-title":"Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro","volume":"34","author":"Yu","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.115.011411_bib649","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejps.2013.12.003","article-title":"Inhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenols","volume":"53","author":"Yuan","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/pr.115.011411_bib650","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/abbi.1995.1438","article-title":"Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform","volume":"322","author":"Zeldin","year":"1995","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/pr.115.011411_bib651","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1128\/MCB.21.8.2838-2846.2001","article-title":"The peptide near the C terminus regulates receptor CAR nuclear translocation induced by xenochemicals in mouse liver","volume":"21","author":"Zelko","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1124\/pr.115.011411_bib652","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/dmd.106.011932","article-title":"Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar","volume":"35","author":"Zhang","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib653","doi-asserted-by":"crossref","first-page":"496","DOI":"10.18433\/J30593","article-title":"Inhibition of human liver cytochrome P450 by star fruit juice","volume":"10","author":"Zhang","year":"2007","journal-title":"J Pharm Pharm Sci"},{"key":"10.1124\/pr.115.011411_bib654","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3109\/00498250903271989","article-title":"C-7 configuration as one of determinants in taxanes metabolism by human cytochrome P450 enzymes","volume":"39","author":"Zhang","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib655","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/00498250802714907","article-title":"Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel","volume":"39","author":"Zhang","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.115.011411_bib656","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.bcp.2009.08.003","article-title":"Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide","volume":"78","author":"Zharikova","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.115.011411_bib657","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.fct.2014.03.004","article-title":"Evaluation of the in vitro\/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition\/induction and UDP-glucuronosyltransferase inhibition","volume":"68","author":"Zheng","year":"2014","journal-title":"Food Chem Toxicol"},{"key":"10.1124\/pr.115.011411_bib658","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.fct.2013.04.053","article-title":"Inhibitory effects of astaxanthin, \u03b2-cryptoxanthin, canthaxanthin, lutein, and zeaxanthin on cytochrome P450 enzyme activities","volume":"59","author":"Zheng","year":"2013","journal-title":"Food Chem Toxicol"},{"key":"10.1124\/pr.115.011411_bib659","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000342120","article-title":"Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis","volume":"129","author":"Zhong","year":"2013","journal-title":"Acta Haematol"},{"key":"10.1124\/pr.115.011411_bib660","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/dmd.110.037143","article-title":"In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics","volume":"39","author":"Zhou","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.115.011411_bib661","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/bdd.706","article-title":"Contributions of human cytochrome P450 enzymes to glyburide metabolism","volume":"31","author":"Zhou","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.115.011411_bib662","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/jphp.12281","article-title":"Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro","volume":"66","author":"Zhu","year":"2014","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/pr.115.011411_bib663","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0024-3205(02)01913-6","article-title":"Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity","volume":"71","author":"Zou","year":"2002","journal-title":"Life Sci"},{"key":"10.1124\/pr.115.011411_bib664","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.112.045575","article-title":"Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19","volume":"40","author":"Zvyaga","year":"2012","journal-title":"Drug Metab Dispos"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724011724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724011724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pr.115.011411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T10:47:36Z","timestamp":1739875656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724011724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":680,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0031699724011724"],"URL":"https:\/\/doi.org\/10.1124\/pr.115.011411","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pr.115.011411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}